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Objective: Congestive heart failure complicating aortic regurgitation is poorly described, and predictive roles of
quantitative versus traditional (symptoms or low ejection fraction) surgical markers are unclear.
Methods: We prospectively enrolled 287 patients with aortic regurgitation (age, 61  17 years; 68% male) in
whom we performed quantitative Doppler echocardiographic analysis and personal physicians conducted
management.
Results: After diagnosis, 40 congestive heart failure episodes occurred under medical management (10-year,
23%  4%) causing high subsequent mortality (hazard ratio [HR], 2.8; 95% confidence interval [CI], 1.2–
6.8; P¼ .02). Patients with traditional surgical markers (symptoms or ejection fraction<50%) were surprisingly
followed 1.4  3.3 years under medical management with frequent congestive heart failure (adjusted risk, 4.9;
95% CI, 2.1–11.0; P< .001) and excess postoperative mortality (HR, 3.0; 95% CI, 1.3–7.1; P ¼ .01). Quanti-
tative American Society of Echocardiography aortic regurgitation grading and left ventricular end-systolic
volume index independently predicted congestive heart failure (quantitative American Society of Echocardiog-
raphy severe aortic regurgitation: HR, 3.6; 95% CI, 1.3–13.0; P¼ .015; end-systolic volume index45 mL/m2:
HR, 2.1; 95% CI, 1.03–4.4; P ¼ .04) or death–congestive heart failure with incremental predictive value (P<
.001). Higher congestive heart failure rates occurred with quantitative American Society of Echocardiography
severe aortic regurgitation (regurgitant volume of60 mL/beat or orifice of30 mm2) versus quantitative Amer-
ican Society of Echocardiography mild aortic regurgitation (10-year: 44% 10% vs 15% 7%, P<.001) and
end-systolic volume index of 45 mL/m2 or greater versus less than 45 mL/m2 (33%  7% vs 9%  2%,
P<.001). Traditional markers (symptoms and ejection fraction<50%) had lower sensitivity for congestive heart
failure than quantitative echocardiography (all P< .001). Cardiac surgery for aortic regurgitation markedly re-
duced congestive heart failure in quantitative American Society of Echocardiography severe aortic regurgitation
(HR, 0.23; 95% CI, 0.08–0.68; P ¼ .008) without excess mortality (P ¼ .10).
Conclusion: This prospective study of aortic regurgitation shows frequent congestive heart failure under conser-
vative management. Traditional surgical markers (symptoms and ejection fraction<50%) predict subsequent
congestive heart failure but are insensitive, and rescue operations are often delayed and associated with excess
mortality. Quantitative echocardiography provides congestive heart failure predictors that are independent, incre-
mental, and more sensitive than traditional markers. Cardiac surgery for aortic regurgitation markedly reduces
congestive heart failure rates in high-risk patients with aortic regurgitation.A
C
DCongestive heart failure (CHF) is a dreaded complication of
cardiac disease, which remains challenging in valvular heart
disease despite the availability of valvular surgery.1 In pa-
tients with aortic regurgitation (AR), data regarding CHF
are sketchy and discordant, leaving doubts regarding its rates
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of specific AR severity measures.6 Limited data suggest
poor outcome after CHF in patients with AR.7,8 Thus defin-
ing patients’ subsets at high CHF risk is crucial to the risk-
stratification process.
In clinical guidelines risk stratification in AR is essentially
based on symptoms or reduced ventricular function.1,9
These traditional surgical markers play a central role because
they are considered the strongest predictors of outcome.2
However, when surgical intervention is performed with
these traditional markers, symptoms usually improve, but
surgical series suggest that survival might remain subopti-
mal.10,11 These dubious outcomes warrant new risk-stratifi-
cation tools to provide better outcomes.
Quantitative echocardiography codified by the American
Society of Echocardiography (quantitative American Soci-
ety of Echocardiography [QASE] grading)6 might play anrdiovascular Surgery c Volume 136, Number 6 1549
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DAbbreviations and Acronyms
AR ¼ aortic regurgitation
CHF ¼ congestive heart failure
CI ¼ confidence interval
EF ¼ ejection fraction
ERO ¼ effective regurgitant orifice
ESVI ¼ end-systolic volume index
HR ¼ hazard ratio
LV ¼ left ventricular
QASE ¼ quantitative American Society of
Echocardiography
RVol ¼ regurgitant volume
important role in AR. For this purpose, we conducted a pro-
spective study in patients with quantified AR and ventricular
volumes using Doppler echocardiography. Pilot data from
the asymptomatic segment of this study were encouraging
by showing a link between these novel variables and the
combined end point of cardiac events.12 However, clinically
relevant issues are whether these quantitative echocardio-
graphic variables specifically predict CHF occurrence and
have an incremental role over symptoms and ejection frac-
tion (EF) and whether these various types of predictors affect
not only medical but also surgical outcome.13 Thus we hy-
pothesized that CHF is frequent in AR treated medically
and that quantitative echocardiography independently and
incrementally (over symptoms and EF) predicts CHF and
defines high-risk groups. We also hypothesized that surgical
intervention for AR reduces the risk of CHF, with excellent
survival in the quantitatively defined high-risk subsets.
MATERIALS AND METHODS
Study Population
The study was approved by the institutional review board, and patients
were consecutively and prospectively enrolled after oral consent between
1990 and 2003 (1) if they had AR that was at least mild, as determined
by means of standard color flow imaging14; (2) if they had AR that was
pure (no stenosis) and isolated (no other valve disease); and (3) if they un-
derwent quantitative echocardiography performed by the investigators with
measurement of AR degree and left ventricular (LV) volumes. Exclusion
criteria were (1) aortic dissection or ongoing endocarditis; (2) functional
AR caused by hypertension; (3) associated aortic systolic gradient of 20
mm Hg or greater; (4) concomitant mitral, congenital (other than bicuspid
valve), or pericardial disease; or (5) previous valve repair or replacement.
Clinical Evaluation and Management
Patients were evaluated and treated by their independent personal physi-
cians who assessed symptoms, were informed of all results, and made all
management decisions (without interference from investigators). Follow-
up, collected after closure of enrollment and of all baseline data-collection
procedures, was complete up to death or 2006 in 95% of patients and was
less than 1 year in only 1.7% of patients. CHF ascertainment used Framing-
ham criteria,15 and documentation of patients’ clinical events was reviewed
to assess these criteria. Symptoms alone were not sufficient for CHF diag-1550 The Journal of Thoracic and Cardiovascular Sunosis, and congestive manifestations were required. Comorbidity assess-
ment used the Charlson index.16
Doppler Echocardiographic Analysis
Quantitation of AR. Comprehensive AR quantitation used 3 vali-
dated methods that were eventually averaged to calculate both regurgitant
volume (RVol) and effective regurgitant orifice (ERO) area (85% of pa-
tients had 2 or 3 methods). These were quantitative Doppler scanning based
on aortic and mitral stroke volume measurement,17,18 quantitative 2-dimen-
sional echocardiography based on LV and mitral stroke volume,18,19 and
a proximal isovelocity surface area method analyzing proximal flow conver-
gence.20 QASE guidelines regarding AR grading6 define QASE severe AR
as an RVol of 60 mL/beat or greater or an ERO area of 30 mm2 or greater,
QASEmild AR as both an RVol of less than 30mL/beat and an ERO area of
less than 10 mm2, and QASE moderate AR as greater than mild criteria
(RVol30 mL/beat or ERO area10 mm2) but not reaching QASE severe
criteria. Color flow imaging jet width/LV outflow tract width ratio14 was
also prospectively measured from parasternal long-axis views.6
LV assessment. LV end-diastolic and end-systolic volume indexes
(ESVIs) and EF determined by using the Simpson disk method and LV
mass were measured as recommended by the American Society of Echocar-
diography.19 LV diameters using M-mode echocardiography were mea-
sured as absolute values and normalized to body surface area.
Statistical Analysis
Data are presented as mean values standard deviations or percentages.
Group comparisons used analysis of variance or the c2 test, as appropriate.
The main outcome end point was CHF occurrence under medical manage-
ment (censored at surgical intervention), and the entire follow-up after
diagnosis was used to assess the effect of surgical intervention as a time-
dependent variable. Survival after surgical intervention was also analyzed.
A secondary end point was combined CHF or death event. Event rates (es-
timated standard error) with the Kaplan–Meier method were compared by
using the log-rank test. Time to CHF (or CHF death) was analyzed bymeans
of the Cox proportional hazard method, with calculation of risk ratio unad-
justed and adjusted for age, sex, and comorbidity score. The main variables
of interest in predicting CHF were baseline symptoms, EF, ESVI, and
QASE AR grading.
RESULTS
Baseline Characteristics
The 287 patients enrolled in the cohort were followed for
7.7  4.0 years. Their baseline characteristics are presented
in Table 1. Some data on the asymptomatic segment of this
population were previously presented.12 Symptoms at pre-
sentation were observed in 25 (9%) patients, and LV dys-
function (EF<50%) was observed in 17 (6%) patients.
These 2 patient subsets had greater LV volume and mass
and lower EF (all P< .001) but showed no difference in
age (both P> .22), sex (both P> .34), or comorbidity
(both P> .49) compared with the cohort remainder. Causes
of AR were degenerative in 53%, congenital in 22%, aortic
root dilatation in 12%, chronic endocarditic lesions in 4%,
rheumatic in 3%, and miscellaneous in 6%. QASE grading1
was 18% QASE mild, 40% QASE moderate, and 42%
QASE severe AR (Table 1). With higher grade, there were
more symptoms, lower EF, and greater LV dilatation and
hypertrophy and jet size (Table 1). Vasodilator therapies dur-
ing medical follow-up were angiotensin-converting enzymergery c December 2008
Detaint et al Acquired Cardiovascular DiseaseTABLE 1. Baseline characteristics of patients according to quantitative assessment of AR and their association with CHF under conservative
management
AR grading*
Overall population
(n ¼ 287)
QASE mild
(n ¼ 52)
QASE moderate
(n ¼ 114)
QASE severe
(n ¼ 121)
P
value
Association with
time to CHF, P value
Clinical characteristics
Age, y 61  17 63  15 62  18 59  18 .25 .003
Male sex, no. (%) 194 (68) 23 (44) 69 (60) 102 (84) <.001 .12
Atrial fibrillation, no. (%) 18 (6) 1 (2) 8 (7) 9 (7) .24 .03
History of hypertension, no. (%) 123 (46) 27 (59) 53 (49) 43 (39) .06 .54
History of coronary artery disease, no. (%) 44 (16) 8 (15) 17 (15) 19 (16) .99 .02
Charlson comorbidity index, arbitrary units 1.9  2.3 1.4  2.0 2.2  2.5 1.9  2.3 .08 .001
Symptoms, no. (%) 25 (9) 0 (0) 2 (2) 23 (19) <.001 <.001
Echocardiographic characteristics
Ejection fraction,% 66  11 70  9 67  10 64  11 .002 <.001
End-systolic diameter index, mm/m2 19  4 17  3 19  4 21  5 <.001 <.001
End-diastolic volume index, mL/m2 109  29 74  17 114  22 136  38 <.001 <.001
End-systolic volume index, mL/m2 39  22 22  11 33  18 50  27 <.001 <.001
Left ventricular mass, g 257  80 188  58 235  73 307  97 <.001 <.001
AR parameters
Jet to outflow tract width ratio,% 40  14 27  12 36  13 50  16 <.001 .13
Regurgitant volume, mL/beat 57  22 17  5 41  12 89  31 <.001 <.001
Effective regurgitant orifice, mm2 26  12 7  2 18  6 42  18 <.001 <.001
AR, Aortic regurgitation;CHF, congestive heart failure;QASE, quantitative American Society of Echocardiography. *QASE severe AR is defined as a regurgitant volume of 60mL/
beat or greater or an effective regurgitant orifice area of 30 mm2 or greater, QASE mild AR is defined as a regurgitant volume of less than 30 mL/beat and an effective regurgitant
orifice ara of less than 10 mm2, and QASE moderate AR is defined as regurgitation greater than QASE mild (regurgitant volume 30 mL/beat or effective regurgitant orifice 10
mm2) but not reaching QASE severe criteria.A
C
Dinhibitors in 116 patients, calcium-channel blockers in 58
patients, and angiotensin receptor blockers in 37 patients.
CHF Rates and Determinants Under Medical
Management
Follow-up under conservative management was 1492 pa-
tient-years, with survival of 91% 2% and 77% 4% at 5
and 10 years, respectively. Remarkably, patients with symp-
toms or EF of less than 50% were followed for 1.4  3.3
years under medical management. Reasons for deferral of
surgical intervention were multiple but essentially reflected
that patients were considered well or improved with medical
treatment while patient preference and comorbidity seldom
justified surgical delay. Under conservative management,
40 episodes of CHF occurred with 5- and 10-year rates of
15%  2% and 23%  4%, respectively. CHF occurrence
was associated with almost tripling of subsequent mortality
(adjusted hazard ratio [HR], 2.8; 95% confidence interval
[CI], 1.2–6.8; P ¼ .02).
Univariate baseline predictors of CHF under conservative
management are listed in Table 1. Traditional surgical
markers (symptoms and EF) were linked to CHF. Quantita-
tive variables, ESVI (HR, 1.04; 95%CI, 1.02–1.05 [per mil-
liliter per square meter]; P< .001), RVol (HR, 1.19; 95%
CI, 1.10–1.29 [per 10 mL/beat]; P< .001), and ERO area
(HR, 1.49; 95% CI, 1.25–1.72 [per 10 mm2]; P< .001)
were also powerful univariate CHF predictors. Table 2The Journal of Thoracic and Cshows that AR quantitation predicted CHF (with or without
adjustment) and that QASE severe versus QASE mild grad-
ing implied quadrupling of CHF risk. QASE moderate grad-
ing was not independently associated with CHF. Prediction
of CHF by means of QASE grading was not affected by va-
sodilator therapy (P<.004). The other independent determi-
nants of CHF adjusting for age, sex, and comorbidity were
symptoms (P< .01) and LV dysfunction assessment based
on either an EF of less than 50% (P< .001) or an ESVI
of 45 mL/m2 or greater (P< .01).
Table 3 shows that adjusting for age, sex, and comorbidity
and grouping traditional surgical indicators (symptoms or
EF<50%), quantitative variables, ESVI of 45 mL/m2 or
greater (P¼ .04), and QASE severe AR (P¼ .015) indepen-
dently predicted CHF under conservative management and
provided incremental predictive power (overall c2 incre-
ment ¼ 17, P< .001).
Five-year CHF rates under medical management were
65%  17% with and 12%  2% without traditional sur-
gical indicators (symptoms or EF<50%, P< .001); were
2%  2%, 12%  3%, and 28%  6% for QASE mild,
moderate, or severe AR (P< .001, Figure 1); and were
33%  7% with an ESVI of 45 mL/m2 or greater and 9%
 2% with an ESVI of less than 45 mL/m2 (P< .001,
Figure 2).
History of clinical coronary disease and baseline atrial
fibrillation were univariate CHF predictors but lostardiovascular Surgery c Volume 136, Number 6 1551
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DTABLE 2. CHF risk under conservative management associated with baseline regurgitant volume, effective regurgitant orifice area, and QASE
severe AR*
Regurgitant volume Effective regurgitant orifice QASE severe AR*
Models Hazard ratio (95% CI)y P value Hazard ratio (95% CI)z P value Hazard ratio (95% CI)x P value
Unadjusted 1.19 (1.1–1.3) <.001 1.49 (1.3–1.7) <.001 5.7 (2.2–19.8) <.001
Adjusted for age, sex, ESVI, NYHA,
comorbidity
1.18 (1.1–1.3) .0015 1.35 (1.1–1.3) .004 4.3 (1.4–16.4) .009
Adjusted for age, sex, EF, NYHA,
comorbidity
1.24 (1.1–1.4) <.001 1.4 (1.2–1.7) <.001 5.9 (2.1–21.4) <.001
CHF, Congestive heart failure; QASE, quantitative American Society of Echocardiography; AR, aortic regurgitation; 95% CI, 95% confidence interval; ESVI, end-systolic volume
index; NYHA, New York Heart Association; EF, ejection fraction. *QASE severe AR is defined as a regurgitant volume of 30 mL/beat or greater or an effective regurgitant orifice
area of 20 mm2 or greater, QASE mild AR is defined as a regurgitant volume of less than 30 mL/beat and an effective regurgitant orifice area of less than 10 mm2. yPer 10-mL/beat
increment. zPer 10-mm2 increment. xUsing QASE mild AR grading as comparison.significance in multivariate analysis and did not affect RVol,
ERO area, QASE severe grading, and ESVI prediction (all
P< .01).
For the combined end point of death–CHF (the endpoint
of CHF or death) under conservative management (68
events), traditional surgical indicators (symptoms or EF
<50%; HR, 2.9; 95% CI, 1.3–5.8; P ¼ .01), ESVI of 45
mL/m2 or greater (HR, 1.9; 95% CI, 1.1–3.4; P ¼ .02),
and QASE severe AR (HR, 3.1; 95% CI, 1.4–7.3; P ¼
.004) were independent predictors. Addition of quantitative
echocardiographic variables provided incremental power
(model c2 increment ¼ 21, P< .001).
Predictive Value of Quantitative Versus Traditional
CHF Markers
Yearly CHF rates and numbers of events are displayed for
traditional indicators (symptoms and EF<50%) in Figure 3
and for newer quantitative parameters (QASE grade and
ESVI45 mL/m2) in Figure 4. Patients with baseline symp-
toms (Figure 3) had high CHF yearly rates (43.2 vs 2.5 per
100 patient-years, P<.001), contrasting with small number
of CHF events predicted (n ¼ 5, 12.5% of CHF events). In
contrast, QASE grading (Figure 4) shows less impressive
difference in CHF rates (6.7 vs 2.0 vs 1.0 per 100 patient-1552 The Journal of Thoracic and Cardiovascular Suyears for QASE severe versus moderate versus mild AR,
P< .001), but most CHF events are detected by QASE
severe AR grading (n ¼ 22, 55% of CHF events). Thus
symptoms showed higher specificity (P < .001), and
QASE grading showed higher sensitivity (P< .001). Simi-
larly, an EF of less than 50% was associated with high
CHF rates (20.7 vs 2.7 per 100 patient-years, P< .001)
but detected only 15% of CHF episodes (Figure 3), whereas
an ESVI of 45 mL/m2 or greater was associated with a less
striking difference in CHF rates (8.5 vs 1.6 per 100 patient-
years, P< .001) but detected most CHF episodes (52.5%,
Figure 4). Thus an EF of less than 50% had higher specific-
ity (P< .001), and an ESVI of 45 mL/m2 or greater had
a higher sensitivity (P<.001). Patients with both QASE se-
vere AR and an ESVI of 45 mL/m2 or greater incurred fre-
quent CHF (48%  10% at 5 years and 69%  13% at
10 years or 14.4% per 100 patient-years) close to that of pa-
tients with symptoms or low EF.
Traditional AR measures (jet-width ratio by means of
color flow imaging6 and LV end-systolic diameter normal-
ized or not to body surface area2,21) univariately predicted
CHF under conservative management (all P< .001) but
lost significance when adjusting for quantitative AR grad-
ing, the significance of which remained unaffected (allTABLE 3. CHF risk under conservative management associated with traditional surgical markers, ESVI of 45 mL/m2 or greater, and QASE
severe AR
Traditional surgical
markers (symptoms or EF<50%) ESVI 45 mL/m2 QASE severe AR*
Models Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Unadjusted 1.18 (1.1–1.3) <.001 4.6 (2.5–8.7) <.001 5.7 (2.2–19.8) <.001
Adjusted for age, sex,
comorbidity
8.3 (3.7–17.6) <.001 3.9 (2.0–7.8) <.001 5.4 (1.9–19.5) <.001
Fully adjusted modely 4.9 (2.1–11.0) <.001 2.1 (1.03–4.4) .04 3.6 (1.3–13.0) .015
c2 Incrementz 21 <.001 6 .02 11 .005
CHF, Congestive heart failure; ESVI, end-systolic volume index;QASE, quantitative American Society of Echocardiography; AR, aortic regurgitation; EF, ejection fraction. *Using
QASE-Mild AR grading as comparison. QASE severe AR is defined as a regurgitant volume of 30 mL/beat or greater or an effective regurgitant orifice area of 20 mm2 or greater,
QASE mild AR is defined as a regurgitant volume of less than 30 mL/beat and an effective regurgitant orifice area of less than 10 mm2. yModel with age, sex, comorbidity, tra-
ditional surgical markers, ESVI of 45 mL/m2 or greater, and QASEmoderate and QASE severe AR. zSequentially modeled c2 increment for traditional surgical markers (symptoms
or EF<50%) over age, sex, and comorbidity; then for ESVI of 45 mL/m2 or greater added (middle panel); and then for QASE severe AR added (right panel). Note that QASE
severe AR is incremental over ESVI, which is incremental over traditional surgical markers (symptoms or EF<50%), which are incremental over age, sex, and comorbidity.rgery c December 2008
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than QASE grading (all P < .001) and ESVI (all P <
.001). For death or CHF under conservative management,
quantitative echocardiography had incremental sensitivity
over traditional surgical indicators (symptoms or EF
<50%, 11/68 events [16%]) of an ESVI of 45mL/m2 or
greater (28/68 events [41%], P< .001) and QASE severe
AR (30/68 events [44%], P< .001).
Cardiac Surgery and Clinical Outcome
A total of 106 patients underwent cardiac surgery for AR
during follow-up for symptoms in 56 patients, LV dysfunc-
tion in 16 patients, aortic dilatation in 14 patients, endocar-
ditis in 4 patients, and physician/patient preference in 16
patients. After surgical intervention for AR, 24 deaths
were noted, with a 5-year survival of 83% 4%. Adjusting
for age, sex, and comorbidity, symptoms or an EF of less
than 50% at diagnosis was associated with excess postoper-
ative mortality (HR, 3.0; 95% CI, 1.3–7.1; P ¼ .01). Five-
year postoperative survival was 63%  10% with
traditional surgical markers at diagnosis versus 89% 
4% without (P< .001). Conversely, a preoperative ESVI
of 45 mL/m2 or greater (P ¼ .09) or QASE severe AR
(P ¼ .10) was not independently associated with excess
postoperative mortality.
During 710 patient-years after surgical intervention, 6
episodes of CHF occurred so that surgical intervention
FIGURE 1. Congestive heart failure (CHF) event rates after the diagnosis
of aortic regurgitation (AR) under medical management according to quan-
titative American Society of Echocardiography (QASE)AR grading. QASE
severe AR is defined as a regurgitant volume of 60 mL/beat or greater or an
effective regurgitant orifice area of 30 mm2 or greater, QASE mild AR is
defined as a regurgitant volume of less than 30 mL/beat and an effective
regurgitant orifice area of less than 10 mm2, and QASE moderate AR is
defined as greater than QASE mild criteria (regurgitant volume 30 mL/
beat or effective regurgitant orifice area 10 mm2) but not reaching
QASE severe criteria. The numbers associated with each curve indicate
the 5-year and 10-year CHF rate  standard error.The Journal of Thoracic and Caas a time-dependant variable (accounting for time to oper-
ation) decreased CHF risk for patients with QASE severe
AR (linearized yearly rate of CHF ¼ 6.7%, decreasing to
0.9%; HR, 0.23; 95% CI, 0.08–0.68; P ¼ .008). Con-
versely, in patients with QASE moderate AR, there was
no detectable CHF difference (P ¼ .84). Adjusting for
age, sex, symptoms, comorbidity, LV function, and
QASE AR grading, surgical intervention for AR markedly
reduced CHF (adjusted HR, 0.14; 95% CI, 0.05–0.41;
P ¼ .0003).
DISCUSSION
The present prospective cohort of patients with AR
shows that CHF is frequent after AR diagnosis and is asso-
ciated with excess subsequent mortality. In routine clinical
practice, despite the presence of traditional surgical markers
(symptoms or EF<50%) in patients with age and comor-
bidity similar to those of our entire cohort, surgical interven-
tion is often delayed, resulting in high rates of CHF and
death–CHF under medical management. Also worrisome
is the association of traditional surgical markers with excess
mortality after surgical intervention. In contrast, novel
quantitative markers (QASE AR grading and ESVI 45
mL/m2) have distinctive clinical value as independent
CHF predictors under medical management. Patients with
QASE severe AR (RVol 60 mL/beat or ERO 30 mm2)
incur CHF 3 to 6 times more frequently than with QASE
mild AR, and QASE grading superseded traditional markers
of severe AR (color jet assessment and LV diameters). Pa-
tients with ESVIs of 45 mL/m2 or greater incur doubling of
CHF risk. Importantly, symptoms and EF of less than 50%
are specific, with very high rates of subsequent CHF (>20
FIGURE 2. Congestive heart failure (CHF) event rates after the diagnosis
of aortic regurgitation under medical management according to the left ven-
tricular end-systolic volume index (ESVI;<45 or 45 mL/m2). The num-
bers associated with each curve indicate the 5-year and 10-year CHF rate
 standard error.rdiovascular Surgery c Volume 136, Number 6 1553
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QASE grading and an ESVI of 45 mL/m2 or greater are
associated with less striking CHF rates (6-9 per 100 pa-
tient-years) but are more sensitive. In these high-risk quan-
titatively defined subsets, cardiac surgery markedly reduces
CHF risk without excess postoperative mortality. Thus res-
cue operations in patients with traditional surgical markers
(symptoms and EF<50%) should be emphasized but are
not sufficient in view of the mediocre postoperative out-
come of these patients. In contrast, quantitative echocardio-
graphic indices allow restorative indications of surgical
intervention for AR, which reduces CHF risk without
excess mortality.
Rationale of the Study
In patients with isolated AR, CHF development has been
insufficiently studied. Rates of CHF complicating AR are
rarely mentioned,2 and most often composite end points
were the main measures of outcome.3,4,22 Thus rates and pre-
dictors and effect on outcome of CHF are unclear.2-5 These
FIGURE 3. Linearized yearly rate of congestive heart failure (CHF; left histograms) and number of CHF events (right histograms) observed according to
stratification by the presence or absence of symptoms at baseline (left panel) or by baseline ejection fraction of 50% or greater or less than 50% (right panel).
Note the high yearly rate of CHF in the subsets with symptoms or an ejection fraction of less than 50% at baseline but also the low actual number of CHF
events in these subsets, demonstrating the low sensitivity of these predictors.
FIGURE 4. Linearized yearly rate of congestive heart failure (CHF; left histograms) and number of CHF events (right histograms) observed according to
stratification by end-systolic volume index (ESVI) greater than and less than 45 mL/m2 (left panel) or by quantitative American Society of Echocardiography
(QASE) AR grading (right panel). QASE severe AR is defined as a regurgitant volume of 60 mL/beat or greater or an effective regurgitant orifice area of 30
mm2 or greater, QASE mild AR is defined as a regurgitant volume of less than 30 mL/beat and an effective regurgitant orifice area of less than 10 mm2, and
QASE moderate AR as greater than QASE mild criteria (regurgitant volume 30 mL/beat or effective regurgitant orifice area 10 mm2) but not reaching
QASE severe criteria. Note the high CHF rates in the subsets with ESVIs of 45 mL/m2 or greater or QASE severe AR but also the high actual number of
CHF events in these subsets, demonstrating the high sensitivity of these predictors.1554 The Journal of Thoracic and Cardiovascular Surgery c December 2008
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Ddifferences might result from patient selection but also from
differences in AR severity that might not have been uncov-
ered by using the crude noninvasive AR assessment avail-
able at the time.2-5
Most importantly, ARmanagement is essentially guided by
traditional surgicalmarkers (symptomsor lowEF),1 anda strat-
egy of symptom-guided management was emphasized as safe
andmost appropriate forpatientswith isolatedAR.23However,
other studies raised concerns regarding outcomewith this strat-
egy, even after surgical correction.8,10 Thus doubts remain on
the respective value of traditional surgical markers (symptoms
or low EF) and emerging quantitative measures. Quantitative
echocardiography6,19 measures absolute AR degree (RVol or
ERO) and LV volumes and in our experience is useful in
asymptomatic patients12 in contrast to the rudimentary
methods previously available,1,9 but its predictive andmanage-
ment values, relative to symptoms and EF, are undefined.
CHF and AR
In this prospective study we observed that CHF occurs
relatively frequently overall (5.2 per 100 patient-years)2
but with considerable differences between subsets of pa-
tients. Patients with QASE mild AR rarely incur CHF,
whereas other subsets incur much higher rates. We found
that baseline symptoms, LV characteristics, and quantified
severity of AR independently predict CHF. Symptoms
and an EF of less than 50% are known to influence outcome
and are listed in current guidelines.1,9 However, the link to
outcome is not sufficient, and it is essential to analyze sen-
sitivity and specificity of CHF prediction in clinical prac-
tice. CHF in AR has been linked to reduced EF,24 and
indeed, we also observe that an EF of less than 50% pre-
dicts high CHF rates. Reduced EF also predicts lower sur-
vival with medical management2 and is considered
a strong indication of surgical intervention.1,9 Similarly,
baseline symptoms, which are known to affect survival,2
are associated in our study with high CHF rates, despite im-
provement with medical treatment. However, outcome with
these traditional surgical markers raises several concerns.
First, despite existing guidelines,1,9 in routine clinical prac-
tice surgical intervention for patients with these traditional
surgical markers is often delayed, leading to frequent
CHF and excess mortality. Second, in agreement with pre-
vious surgical series,10,11,25 excess mortality follows opera-
tions performed for symptoms or reduced EF, which
represent late indicators of rescue operations rather than re-
storative operations conducive to favorable postoperative
outcomes.13 Third, symptoms and low EF are insufficient23
because they are insensitive and detect only a small minor-
ity of the CHF events to come. Therefore in view of the ex-
cess mortality after CHF and of the reduction of CHF risk by
AR surgery, our data unquestionably show that additional
predictors of outcome are needed to more sensitively pre-
dict CHF events and poor outcome.The Journal of Thoracic and COur results verify the hypotheses that quantitative echo-
cardiography provides objective indices (quantitative AR
grading and ESVI) that can alleviate the CHF burden in pa-
tients with AR. These measures independently predict CHF
incrementally to symptoms and EF and with higher sensitiv-
ity. In high-risk patients examined by using quantitative
measures, surgical intervention for AR is not associated
with excess mortality (as it is for symptoms and low EF)
and reduces the risk of CHF.
Although qualitative AR degree predicts CHF, it is super-
seded by quantitative grading, emphasizing the importance
of the quantitative approach.6 Our prospective data show
that QASE severe AR is the most sensitive CHF predictor,
filling a demand unmet by other outcome predictors.13
Low CHF rates with QASE mild AR probably represent
the background population CHF rate, which is inconsistently
associated with low EF.26 In contrast to this background rate,
QASE severe AR multiplies CHF risk between 3 and 6
times. LV volume measurements provide another important
independent CHF predictor. End-systolic LV characteristics
predict outcome under medical management2,4 and after sur-
gical intervention.27 Importantly, ESVI supersedes LV di-
ameters (even adjusted for body surface area) and is more
sensitive than EF; that is, the measures currently in clinical
guidelines1,2,27 and an ESVI of 45 mL/m2 or greater apply
equally to men and women by normalizing to body size.21
Thus this prospective study contrasts value and comple-
mentarity of traditional surgical markers (symptoms and
EF), specific and associated high CHF rates, and novel quan-
titative echocardiographic measures (QASE grading and
ESVI), both sensitive and incremental. Because these
markers carry different implications for postoperative out-
come, they emphasize different clinical implications.
Clinical Implications
Patients with traditional surgical markers (symptoms or
EF<50%) are at high and immediate risk of CHF or death,
irrespective of apparent improvements with medical treat-
ment, but disappointingly, surgical intervention is often de-
layed. Thus our study emphasizes the need for speedy rescue
operations for patients with these ominous characteristics. In
view of excess postoperative mortality in these patients, res-
cue operations should not be the preferred timing of surgical
correction of AR.
Quantitative echocardiographic variables allow restor-
ative surgical intervention without excess postoperative
mortality and with CHF risk reduction. Quantitative AR
grading predicts CHF independently of all other clinical
characteristics incrementally to traditional surgical markers
and supersedes qualitative AR grading. Hence quantitative
AR assessment should be encouraged and generalized.6
Patients with both QASE severe AR and an ESVI of 45
mL/m2 or greater incur a progressive but high risk,12 partic-
ularly of CHF. These characteristics represent the optimalardiovascular Surgery c Volume 136, Number 6 1555
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low postoperative mortality and marked CHF reduction
and thus with the potential to provide true restorative surgi-
cal intervention.
Subsets with isolated QASE severe AR or an ESVI of 45
mL/m2 or greater (but not both) or those with QASE moder-
ate AR are at moderate CHF risk but might progress and
should be monitored closely. Vasodilators for preventing
AR progression are disputed,28,29 and there is no defined
process to stabilize AR or LV function in such patients.
Limitation of the Study
The occurrence of CHF is complex and implies multiple
pathways, and a causal link between AR and CHF is difficult
to prove. Coronary artery disease and atrial fibrillation can
contribute to CHF,30,31 but in the current study they were
not independently predictive. Our scope was not to address
all possible CHF contributors but to focus on AR-specific
CHF prediction.26 The link between AR and CHF is sup-
ported by strong association of CHF rates with AR degree
and by considerable CHF risk reduction after surgical inter-
vention for AR.
Inclusion of baseline symptoms or an EF of less than 50%
might be disputed in that guidelines recommend surgical in-
tervention in such patients. However, our study shows that in
clinical practice physicians inconsistently refer such patients
to surgical intervention, with delays causing CHF events and
death. Thus it is essential to emphasize the need for speedy
rescue operations in such patients. The new observation that
symptoms and EF are specific but insensitive in predicting
CHF in comparison with objective measurements, such as
QASE grading and ESVI, could only be revealed by means
of inclusion, irrespective of symptoms or EF, of all patients
prospectively examined.
CONCLUSION
This prospective cohort of patients with AR shows that
CHF is frequent after diagnosis and is followedby excessmor-
tality. Traditional surgicalmarkers (symptoms and EF<50%)
predict CHF but are insensitive, and rescue operations are of-
ten delayed and associated with excess mortality. QASE se-
vere AR and an ESVI of 45 mL/m2 or greater independently
predict CHF and provide incremental and sensitive prediction
of risk for CHF or for CHF or death. Surgical intervention for
AR markedly reduces CHF risk without excess postoperative
mortality in these high-risk patients with AR and should be
carefully considered in clinical practice.
References
1. Bonow RO, Carabello BA, Kanu C, de Leon AC Jr, Faxon DP, Freed MD, et al.
ACC/AHA 2006 guidelines for the management of patients with valvular heart
disease: a report of the American College of Cardiology/American Heart Associ-
ation Task Force on Practice Guidelines (writing committee to revise the 1998
‘‘Guidelines for the management of patients with valvular heart disease’’): devel-1556 The Journal of Thoracic and Cardiovascular Suoped in collaboration with the Society of Cardiovascular Anesthesiologists: en-
dorsed by the Society for Cardiovascular Angiography and Interventions and
the Society of Thoracic Surgeons. Circulation. 2006;114:e84-231.
2. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ.
Mortality and morbidity of aortic regurgitation in clinical practice. A long-term
follow-up study. Circulation. 1999;99:1851-7.
3. Bonow R, Lakatos E, Maron B, Epstein S. Serial long-term assessment of the nat-
ural history of asymptomatic patients with chronic aortic regurgitation and normal
left ventricular systolic function. Circulation. 1991;84:1625-35.
4. Borer J, Hochreiter C, Herrold E, Supino P, Ascherman M, Wencker D, et al. Pre-
diction of indication for Valve replacement among asymptomatic or minimally
symptomatic patients with chronic aortic regurgitation and normal left ventricular
performance. Circulation. 1998;97:525-34.
5. Tornos MP, Permanyer-Miralda G, Evangelista A, Worner F, Candell J,
Garcia-del-Castillo H, et al. Clinical evaluation of a prospective protocol
for the timing of surgery in chronic aortic regurgitation. Am Heart J.
1990;120:649-57.
6. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA,
et al. Recommendations for evaluation of the severity of native valvular regurgi-
tation with two-dimensional and Doppler echocardiography. J Am Soc Echocar-
diogr. 2003;16:777-802.
7. Spagnuolo M, Kloth H, Taranta A, Doyle E, Pasternack B. Natural history of
rheumatic aortic regurgitation. Criteria predictive of death, congestive heart fail-
ure, and angina in young patients. Circulation. 1971;44:368-80.
8. Turina J, Hess O, Sepulcri F, Krayenbuehl H. Spontaneous course of aortic valve
disease. Eur Heart J. 1987;8:471-83.
9. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al.
Guidelines on the management of valvular heart disease: the Task Force on the
Management of Valvular Heart Disease of the European Society of Cardiology.
Eur Heart J. 2007;28:230-68.
10. Klodas E, Enriquez-Sarano M, Tajik A, Mullany C, Bailey K, Seward J. Optimiz-
ing timing of surgery in patients with chronic severe aortic regurgitation: the role
of symptoms. J Am Coll Cardiol. 1997;30:746-52.
11. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, et al. Out-
comes following aortic valve replacement in patients with severe aortic regurgita-
tion and markedly reduced left ventricular function. Circulation. 2002;106:
2687-93.
12. Detaint D, Messika-Zeitoun D, Maalouf J, Tribouilloy CM, Mahoney DW,
Tajik AJ, et al. Quantitative echocardiographic determinants of clinical outcome
in asymptomatic patients with aortic regurgitation: a prospective study. J Am Coll
Cardiol Img. 2008;1:1-11.
13. Enriquez-Sarano M, Tajik AJ. Clinical practice. Aortic regurgitation. N Engl J
Med. 2004;351:1539-46.
14. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B. Evaluation of aortic insuffi-
ciency by Doppler color flow mapping. J Am Coll Cardiol. 1987;9:952-9.
15. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the on-
set of congestive heart failure in Framingham Heart Study subjects. Circulation.
1993;88:107-15.
16. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prog-
nostic comorbidity in longitudinal studies: development and validation. J Chronic
Dis. 1987;40:373-83.
17. Enriquez-Sarano M, Bailey K, Seward J, Tajik A, Krohn M, Mays J. Quantitative
Doppler assessment of valvular regurgitation. Circulation. 1993;87:841-8.
18. Enriquez-Sarano M, Seward J, Bailey K, Tajik A. Effective regurgitant orifice
area: a noninvasive Doppler development of an old hemodynamic concept.
J Am Coll Cardiol. 1994;23:443-51.
19. Schiller N, Shah P, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al.
Recommendations for quantitation of the left ventricle by two-dimensional echo-
cardiography. American Society of Echocardiography Committee on Standards,
Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am
Soc Echocardiogr. 1989;2:358-67.
20. Tribouilloy CM, Enriquez-Sarano M, Fett SL, Bailey KR, Seward JB, Tajik AJ.
Application of the proximal flow convergence method to calculate the effective re-
gurgitant orifice area in aortic regurgitation. J Am Coll Cardiol. 1998;32:1032-9.
21. Klodas E, Enriquez-Sarano M, Tajik A, Mullany C, Bailey K, Seward J. Surgery
for aortic regurgitation in women: contrasting indications and outcomes as com-
pared with men. Circulation. 1996;1996:2472-8.
22. Tornos MP, Olona M, Permanyer-Miralda G, Herrejon MP, Camprecios M,
Evangelista A, et al. Clinical outcome of severe asymptomatic chronic aortic re-
gurgitation: a long-term prospective follow-up study. Am Heart J. 1995;130:
333-9.rgery c December 2008
Detaint et al Acquired Cardiovascular Disease23. Tarasoutchi F, Grinberg M, Spina GS, Sampaio RO, Cardoso LF,
Rossi EG, et al. Ten-year clinical laboratory follow-up after application
of a symptom-based therapeutic strategy to patients with severe chronic
aortic regurgitation of predominant rheumatic etiology. J Am Coll Cardiol.
2003;41:1316-24.
24. Kraus F, Dacian S, Hall D, Klein U, RudolphW. Relationship between symptoms
and hemodynamics associated with regurgitant lesions of the aortic or mitral
valve. Z Kardiol. 1986;75:137-40.
25. Klodas E, Enriquez-Sarano M, Tajik A, Mullany C, Bailey K, Seward J.
Aortic regurgitation complicated by extreme left ventricular dilatation:
long-term outcome after surgical correction. J Am Coll Cardiol. 1996;
27:670-7.
26. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends
in prevalence and outcome of heart failure with preserved ejection fraction.NEngl
J Med. 2006;355:251-9.The Journal of Thoracic and Car27. Carabello B, Williams H, Gash A, Kent R, Belber D, Maurer A, et al. Hemody-
namic predictors of outcome in patients undergoing valve replacement. Circula-
tion. 1986;74:1309-16.
28. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-
term vasodilator therapy in patients with severe aortic regurgitation.NEngl J Med.
2005;353:1342-9.
29. Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S. Nifedipine in
asymptomatic patients with severe aortic regurgitation and normal left ventricular
function. N Engl J Med. 1994;331:689-94.
30. Villari B, Campbell S, Hess O. Influence of collagen network on left ventricular
systolic and diastolic function in aortic valve disease. J Am Coll Cardiol. 1993;22:
1477-84.
31. Ramsdale D, Bray C, Bennett D, Ward C, Beton D, Faragher E. Routine coronary
angiography is unnecessary in all patients with valvular heart disease. Z Kardiol.
1986;75:61-7.diovascular Surgery c Volume 136, Number 6 1557
A
C
D
